Skip to main content
    I

    Incyte Corporation (INCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $120.27
    -0.70 (-0.58%)

    Market Cap: $24.66B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Incyte Corporation (INCY) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Incyte (INCY) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Incyte reported EPS of -$3.79, above the -$4.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -4.20%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.03
    Range$1.56 - $3.23
    26 analysts
    Revenue Consensus
    $1.58B
    Range$1.46B - $1.69B
    24 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.72
    Range$1.15 - $1.95
    7 analysts
    EPS Revisions
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$1.74-1.5%
    60d ago$1.76-2.5%
    30d ago$1.73-1.1%
    7d ago$1.78-3.6%
    Current$1.72
    Revenue Consensus
    $1.36B
    Range$1.33B - $1.40B
    8 analysts

    Next Report

    INCY has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 12.8% above the $1.80 reported for the quarter ended Dec 31, 2025.

    INCY Earnings Call

    The latest INCY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, INCY beat 21 and missed 19. Revenue for the quarter ended Sep 30, 2026 was $1.56B, up 13.9% from $1.37B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$3.79-$4.27-$4.46 - -$2.85+11.24%Beat-267.7%160 up, 2 downOct 29, 2026$1.56B
    Jun 30, 2026$2.80$1.76$1.63 - $2.85+59.09%Beat+78.3%192 up, 2 downJul 28, 2026$1.67B
    Mar 31, 2026$1.81$1.34$0.90 - $1.68+35.07%Beat+56.0%172 up, 6 downApr 28, 2026$1.27B
    Dec 31, 2025$1.80$1.92$1.71 - $2.18-6.25%Miss+25.9%156 up, 0 downFeb 10, 2026$1.51B
    Sep 30, 2025$2.26$1.64$1.29 - $1.85+37.80%Beat+111.2%164 up, 2 downOct 28, 2025$1.37B
    Jun 30, 2025$1.57$1.47$1.29 - $2.36+6.80%BeatN/A153 up, 2 downJul 29, 2025$1.22B
    Mar 31, 2025$1.16$1.03$0.76 - $1.35+12.62%Beat+81.2%14N/AApr 29, 2025$1.05B
    Dec 31, 2024$1.43$1.55$1.29 - $1.94-7.74%Miss+34.9%147 up, 3 downFeb 10, 2025$1.18B
    Sep 30, 2024$1.07$1.09$0.72 - $1.84-1.83%Miss-2.7%152 up, 4 downOct 29, 2024$1.14B
    Jun 30, 2024-$1.82$1.11N/A-263.96%Miss-283.8%26 up, 2 downJul 30, 2024$1.04B
    Mar 31, 2024$0.64$0.83$0.55 - $1.06-22.89%Miss+73.0%124 up, 1 downApr 30, 2024$880.89M
    Dec 31, 2023$1.06$1.15$0.97 - $1.34-7.83%Miss+71.0%153 up, 0 downFeb 13, 2024$1.01B
    Sep 30, 2023$1.10$1.07$0.63 - $1.21+2.80%Beat+83.3%122 up, 1 downOct 31, 2023$919.02M
    Jun 30, 2023$0.99$0.87$0.58 - $1.23+13.79%Beat-2.0%124 up, 2 downAug 1, 2023$954.61M
    Mar 31, 2023$0.37$0.74$0.46 - $1.00-50.00%Miss-32.7%134 up, 0 downMay 2, 2023$808.67M
    Dec 31, 2022$0.62$0.57$0.39 - $0.76+8.77%Beat+520.0%131 up, 2 downFeb 7, 2023$926.70M
    Sep 30, 2022$0.60$0.71$0.53 - $0.87-15.49%Miss-49.2%122 up, 6 downNov 1, 2022$823.30M
    Jun 30, 2022$1.01$0.75$0.36 - $0.96+34.67%Beat+26.2%124 up, 0 downAug 2, 2022$911.40M
    Mar 31, 2022$0.55$0.69$0.39 - $0.95-20.29%Miss-17.9%91 up, 2 downMay 3, 2022$733.24M
    Dec 31, 2021$0.10$0.87$0.67 - $1.09-88.51%Miss-89.2%113 up, 0 downFeb 8, 2022$862.85M
    Sep 30, 2021$1.18$0.76$0.51 - $0.88+55.26%Beat+413.0%100 up, 0 downNov 2, 2021$812.99M
    Jun 30, 2021$0.80$0.74$0.61 - $0.88+8.11%Beat-35.5%10N/AAug 3, 2021$705.71M
    Mar 31, 2021$0.67$0.64$0.53 - $0.79+4.69%BeatN/A10N/AMay 4, 2021$604.72M
    Dec 31, 2020$0.93$0.77$0.20 - $1.04+20.78%Beat+43.1%12N/AFeb 9, 2021$789.51M
    Sep 30, 2020$0.23$0.76$0.64 - $0.89-69.74%Miss-72.0%12N/ANov 5, 2020$620.64M
    Jun 30, 2020$1.24$0.86$0.55 - $1.29+44.19%Beat+65.3%12N/AAug 4, 2020$688.04M
    Mar 31, 2020-$2.86-$2.80N/A-2.14%Miss-561.3%9N/AMay 5, 2020$568.51M
    Dec 31, 2019$0.65$0.58$0.31 - $0.88+12.07%Beat+62.5%12N/AFeb 13, 2020$579.39M
    Sep 30, 2019$0.82$0.64$0.50 - $0.84+28.13%Beat+115.8%14N/AOct 29, 2019$551.58M
    Jun 30, 2019$0.75$0.50$0.32 - $0.65+50.00%Beat+188.5%12N/AJul 30, 2019$529.93M
    Mar 31, 2019$0.62$0.41$0.24 - $0.60+51.22%BeatN/A13N/AApr 30, 2019$497.86M
    Dec 31, 2018$0.40$0.46$0.20 - $0.61-13.04%MissN/A13N/AFeb 14, 2019$528.40M
    Sep 30, 2018$0.38$0.41$0.33 - $0.53-7.32%Miss+123.5%14N/AOct 30, 2018$449.68M
    Jun 30, 2018$0.26$0.22$0.19 - $0.65+18.18%BeatN/A11N/AJul 31, 2018$521.52M
    Mar 31, 2018-$0.01$0.12-$0.30 - $0.32-108.33%MissN/A11N/AMay 1, 2018$382.28M
    Dec 31, 2017-$0.71-$0.45-$0.64 - $0.09-57.78%Miss-1520.0%18N/AFeb 15, 2018$444.16M
    Sep 30, 2017$0.17$0.06-$0.01 - $0.17+183.33%Beat-10.5%16N/AOct 31, 2017$381.53M
    Jun 30, 2017-$0.06-$0.04-$0.16 - $0.18-50.00%Miss-133.3%13N/AAug 1, 2017$326.44M
    Mar 31, 2017-$0.96-$0.88N/A-9.09%Miss-900.0%N/AN/AMay 4, 2017$384.08M
    Dec 31, 2016$0.05$0.14N/A-64.29%Miss-82.8%N/AN/AFeb 14, 2017$326.50M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.79, up 414.4% from the year before. It was $0.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.79+414.4%
    Dec 31, 2024$1.32-62.5%
    Dec 31, 2023$3.52+26.6%
    Dec 31, 2022$2.78N/A
    Dec 31, 2021$2.75N/A
    Dec 31, 2020-$0.46-116.2%
    Dec 31, 2019$2.84+175.7%
    Dec 31, 2018$1.03N/A
    Dec 31, 2017-$1.56-388.9%
    Dec 31, 2016$0.54N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 23 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,44623
    2026Q2Jun 30, 20268,40120
    2026Q1Mar 31, 20267,54220
    2025Q4Dec 31, 20259,69022
    2025Q3Sep 30, 20258,87820
    2025Q2Jun 30, 20259,44820
    2025Q1Mar 31, 20259,04026
    2024Q4Dec 31, 20248,44422

    2026Q3 Earnings Call

    Opening remarks

    Alexis Smith Vice President, Head of Investor Relations Thank you. Good morning, and welcome to Incyte's third quarter 2026 earnings conference call. Before we begin, I encourage everyone to go to the investor section of our website to find the press release, related financial tables, and slides that follow today's discussion. On today's call, I am joined by Bill, Pablo, and Suky, who will deliver our prepared remarks. Steven, Dave, and Mohamed will also be available for Q&A. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. I will now hand the call over to Bill.

    Bill Meury CEO Thanks, Alexis, and good morning, everyone. As we look at the first nine months of the year, we have made meaningful progress against the strategy we laid out for Incyte. That strategy has two fundamental components: scaling the core business beyond Jakafi and advancing our late-stage pipeline to drive the next phase of growth. The core business is the foundation that gives us the scale to navigate the 2029 transition and fund R&D. Layering the pipeline on top of that gives us the opportunity to build a significantly larger company over the next decade. We now have several compounds in Phase III development, including a mutant CALR antibody for MPNs, a Protein S modulator for von Willebrand disease, a G12D inhibitor for pancreatic cancer, a TGFβ×PD-1 bispecific antibody in colorectal cancer, a CDK2 inhibitor for ovarian cancer, and a JAK inhibitor currently under regulatory review in HS. We have increasing confidence in the biology behind these programs and believe we have taken meaningful risks out of them as they have advanced. That does not mean the risk is zero, but increasingly the risk we are managing is execution risk: running high-quality Phase III programs, enrolling them on time, and achieving the regulatory milestones in front of us. Those are things we directly control, and that is our focus today. We are fully funding and resourcing these opportunities, leaving nothing to chance. If we deliver against them, we believe the value creation potential is substantial, and that is how we should ultimately be judged. Now we will frame the quarter around three themes. First, key business performance. Every product grew year-over-year. Jakafi had another strong quarter with growth across all indications, and sales from our core business, excluding Jakafi, increased 37% from the prior year. Second, we achieved important regulatory milestones, including the approval and launch of OPZELURA for moderate AD in the EU in the third quarter.

    Frequently Asked Questions About INCY

    When is Incyte's next earnings date?

    Incyte's next earnings report is expected for Feb 8, 2027.

    Did INCY beat earnings estimates last quarter?

    Yes. Incyte reported EPS of -$3.79 for the quarter ended Sep 30, 2026, above the -$4.27 estimate, a 11.24% surprise.

    What EPS do analysts expect from INCY next quarter?

    The consensus EPS estimate for Incyte for the quarter ending Dec 31, 2026 is $2.03 from 26 analysts, with estimates from $1.56 to $3.23.

    How often does INCY beat earnings estimates?

    Incyte beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +18.58%.